首页> 外文期刊>Medical Microbiology and Immunology >Comparative multi-assay evaluation of Determine (TM) HIV-1/2 Ag/Ab Combo rapid diagnostic tests in acute and chronic HIV infection
【24h】

Comparative multi-assay evaluation of Determine (TM) HIV-1/2 Ag/Ab Combo rapid diagnostic tests in acute and chronic HIV infection

机译:比较多测定评价确定(TM)HIV-1/2 AG / AB组合在急性和慢性艾滋病毒感染中的快速诊断试验

获取原文
获取原文并翻译 | 示例
       

摘要

In resource-limited or point-of-care settings, rapid diagnostic tests (RDTs), that aim to simultaneously detect HIV antibodies and p24 capsid (p24CA) antigen with high sensitivity, can pose important alternatives to screen for early infections. We evaluated the performance of the antibody and antigen components of the old and novel version of the Determine (TM) HIV-1/2 Ag/Ab Combo RDTs in parallel to quantifications in a fourth-generation antigen/antibody immunoassay (4G-EIA), p24CA antigen immunoassay (p24CA-EIA), immunoblots, and nucleic acid quantification. We included plasma samples of acute, treatment-naive HIV-1 infections (Fiebig stages I-VI, subtypes A1, B, C, F, CRF02_AG, CRF02_AE, URF) or chronic HIV-1 and HIV-2 infections. The tests' antigen component was evaluated also for a panel of subtype B HIV-1 transmitted/founder (T/F) viruses, HIV-2 strains and HIV-2 primary isolates. Furthermore, we assessed the analytical sensitivity of the RDTs to detect p24CA using a highly purified HIV-1(NL4-3) p24CA standard. We found that 77% of plasma samples from acutely infected, immunoblot-negative HIV-1 patients in Fiebig stages II-III were identified by the new RDT, while only 25% scored positive in the old RDT. Both RDTs reacted to all samples from chronically HIV-1-infected and acutely HIV-1-infected patients with positive immunoblots. All specimens from chronically infected HIV-2 patients scored positive in the new RDT. Of note, the sensitivity of the RDTs to detect recombinant p24CA from a subtype B virus ranged between 50 and 200 pg/mL, mirrored also by the detection of HIV-1 T/F viruses only at antigen concentrations tenfold higher than suggested by the manufacturer. The RTD failed to recognize any of the HIV-2 viruses tested. Our results indicate that the new version of the Determine (TM) HIV-1/2 Ag/Ab Combo displays an increased sensitivity to detect HIV-1 p24CA-positive, immunoblot-negative plasma samples compared to the precursor version. The sensitivity of 4G-EIA and p24CA-EIA to detect the major structural HIV antigen, and thus to diagnose acute infections prior to seroconversion, is still superior.
机译:在资源限制或护理点设置中,快速诊断测试(RDT),其目的是同时检测HIV抗体和具有高灵敏度的抗原的抗原,可以为早期感染筛选筛选的重要替代品。我们评估了旧的和新颖版本的抗体和抗原组分的抗体和抗原组分的性能与第四代抗原/抗体免疫测定(4G-EIA)中的量化平行于定量,P24CA抗原免疫测定(P24CA-EIA),免疫印迹和核酸定量。我们包括急性,治疗幼稚HIV-1感染的血浆样品(Fiebig阶段I-VI,亚型A1,B,C,F,CRF02_AG,CRF02_AE,URF)或慢性HIV-1和HIV-2感染。对测试的抗原组分也被评估用于亚型B HIV-1透射/创始人(T / F)病毒,HIV-2菌株和HIV-2初级分离株。此外,我们评估了使用高度纯化的HIV-1(N14-3)P24CA标准来检测P24CA的RDT的分析敏感性。我们发现,77%的血浆样品来自急剧感染,Fiebig阶段II-III患者II-III患者被新的RDT鉴定,而旧的RDT仅均为25%。两个RDT对来自慢性HIV-1感染和急性HIV-1感染患者的阳性免疫细胞的所有样品反应。所有来自慢性感染的HIV-2患者的标本在新的RDT中得分阳性。值得注意的是,RDTS从亚型B病毒检测重组P24CA的敏感性在50至200pg / mL之间,镜像也通过检测HIV-1 T / F病毒,仅在抗原浓度上高于制造商的抗原浓度。 RTD无法识别测试的任何HIV-2病毒。我们的结果表明,与前体版本相比,新版本的确定(TM)HIV-1/2 AG / AB组合的敏感性增加了敏感性,以检测HIV-1P24CA阳性免疫血浆样品。 4G-EIA和P24CA-EIA检测主要结构HIV抗原的敏感性,从而诊断血清转换前的急性感染,仍然优越。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号